METABOLOMIC DIAGNOSTICS LIMITED

Their core work

Metabolomic Diagnostics Limited is an Irish biotech SME that develops blood- or urine-based diagnostic tests for pregnancy complications using metabolomics — the analysis of small-molecule metabolites as biological markers. Their core work involves building the analytical and calibration frameworks needed to measure these biomarkers reliably in clinical settings, then validating them as predictive tools for conditions like preeclampsia. They operate at the intersection of analytical chemistry, clinical medicine, and diagnostic product development, translating metabolomics research into tests suitable for routine antenatal care. Their trajectory from a methodology-focused research project to a large SME Instrument Phase 2 commercialization grant shows a company advancing its own proprietary diagnostic platform toward market.

What they specialise in

How they've shifted over time

Both H2020 projects launched in 2018, so the timeline is compressed, but the shift in funding scheme tells a clear story: PRECALI was an MSCA Individual Fellowship (a researcher hosted by the company to solve a specific technical problem — calibration), while IPOG was an SME Instrument Phase 2 grant of nearly €1.9M (a commercialization instrument for companies with a proven concept ready to scale). This progression from methodology validation to large-scale market entry represents a company that had already done foundational R&D and was using EU funding to move its diagnostic platform into clinical and commercial use. The broadening scope — from one specific condition (preeclampsia) to pregnancy outcomes globally — suggests increasing confidence in the platform's applicability.

They are moving from technical R&D into product commercialization and market scaling — a company looking for clinical validation partners, distribution channels, and regulatory expertise rather than basic research collaborators.

How they like to work

Metabolomic Diagnostics coordinated both of their H2020 projects, with no recorded consortium partners in CORDIS — a pattern typical of SME Instrument grants and MSCA fellowships, where the company is the central entity and academic or clinical collaborators may not appear as formal consortium members. This suggests they are comfortable driving projects independently and likely engage collaborators (hospitals, universities, reference labs) informally or through sub-contracts rather than as co-beneficiaries. For a prospective partner, this means they are likely to lead joint projects, but may prefer focused bilateral arrangements over large multi-partner consortia.

No consortium partners are recorded in CORDIS across either project, which reflects the nature of their funding instruments (MSCA fellowship and SME Instrument) rather than isolation. Their real network almost certainly includes Irish and European clinical research institutions, but these relationships are not visible in the H2020 data.

What sets them apart

Metabolomic Diagnostics is one of a small number of European SMEs that has both the scientific depth to run MSCA-level research and the commercial maturity to win a Phase 2 SME Instrument grant — a combination that signals a company with a defensible proprietary platform, not just a service provider. Their specific niche — metabolomics applied to maternal and perinatal medicine — sits in a diagnostic market with high clinical need and relatively few specialized players. For a consortium builder, they bring both the IP and the regulatory/commercialization experience that academic partners typically lack.

Highlights from their portfolio

• IPOG
  At nearly €1.9M under SME Instrument Phase 2, IPOG is one of the most competitive EU grants available to SMEs and signals that Metabolomic Diagnostics had a validated, market-ready concept for improving pregnancy outcomes globally.
• PRECALI
  PRECALI used an MSCA Individual Fellowship to solve a specific technical bottleneck — calibration for metabolomics-based preeclampsia testing — showing the company's ability to attract and direct research talent toward product-critical problems.